semaglutide oral Approved to Reduce the Risk of Cardiovascular Events RYBELSUS® (semaglutide) tablets 7 mg

healthcare spending exceeded USD 4.5 trillion, supporting strong adoption of advanced therapies like GLP-1 drugs

These determinants are dynamic and may influence both metabolic outcomes and gut microbial composition during therapy

Common side effects include nausea, vomiting, constipation, and mild diarrhea, especially during dose escalation

The GLP-1 analogue market is a pharmaceutical phenomenon, projected to surge from $45.3 billion in 2025 to a staggering $122.3 billion by 2030

Katie Rickel, OrderlyMeds Mental Health Expert May is Mental Health Awareness Month, and if youre on a GLP-1s and Hormonal Changes: Why Your Body Feels Different and May is Womens Health Month and for many of us, its a reminder to pay closer attention to our bodies.